Glucogenolytic and hyperglycemic effect of 33-49 C-terminal fragment of pancreastatin in the rat in vivo.
The effects of the 33-49 C-terminal fragment of pancreastatin on glycogen content, glycemia, insulinemia and glucagonemia were studied in the rat in vivo. It was found that after intramesenteric vein injection of the peptide, the glycogen content of liver decreased compared with control group injected with saline-1 < % BSA. Blood glucose levels were increased by the C-terminal fragment of pancreastatin. This study shows that the 33-49 C-terminal fragment of pancreatasin could play a role in glucose metabolism not mediated by insulin or glucagon.
Sánchez-Margalet
V
V
Departamento de Bioquímica Médica y Biología Molecular, Facultad de Medicina, Universidad de Sevilla, Spain.
Calvo
J R
JR
Goberna
R
R
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005934:Glucagon / Q000097:blood / Q000378:metabolism*; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D000078790:Insulin Secretion; D007700:Kinetics; D008099:Liver / Q000187:drug effects; D008112:Liver Glycogen / Q000378:metabolism*; D008297:Male; D010187:Pancreatic Hormones / Q000494:pharmacology*; D010446:Peptide Fragments / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012016:Reference Values
D001786:Blood Glucose; D007328:Insulin; D008112:Liver Glycogen; D010187:Pancreatic Hormones; D010446:Peptide Fragments; C073861:pancreastatin (33-49); D005934:Glucagon